Substitution of First Phase Insulin Response in Patient With Type 2 Diabetes.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00254085|
Recruitment Status : Unknown
Verified September 2005 by University Hospital, Gentofte, Copenhagen.
Recruitment status was: Recruiting
First Posted : November 15, 2005
Last Update Posted : November 15, 2005
|Condition or disease||Intervention/treatment||Phase|
|Type 2 Diabetes||Drug: Insulin Aspart||Phase 4|
Patients with Type 2 diabtes has a defect in the insulinsecretion combined with an increased insulin resistance. At an intravenously glucosestimulation, patients with Type 2 diabtes has a decresed first phase insulin response compared to healty peoples. Because the hyperglycemia after meal, observed i Type 2 diabetics patients, is related to the defect in the first phase insulin response it is our hypothesis that substitution of the first phase insulin response with a little dose of insulin could normalise the blood glucose after the meal.
20 patients with Type 2 diabetes will in a randomised, placebocontrolled, dobble-dummy study be included for three days treatment with Insulin aspart vs placebo. Primary endpoint is bloodglucose fluctuations monitored by a continously glucose monitor.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||20 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||Multiple Substitution of First Phase Insulin Response With a Rapid Action Insuli Analogue in Patient With Newly Diagnosed Type 2 Diabtes.|
|Study Start Date :||March 2005|
|Study Completion Date :||March 2006|
- Blood glucose fluctuations
- number of hypoglycemia
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00254085
|Contact: Charlotte Gredal, MD||+45 39 77 79 email@example.com|
|Gentofte University Hospital||Recruiting|
|Hellerup, Denmark, 2900|
|Contact: Charlotte Gredal, MD +45 39 77 79 76 firstname.lastname@example.org|
|Principal Investigator: Charlotte Gredal, MD|
|Principal Investigator:||Charlotte Gredal, MD||Gentofte University Hospital|